It is widely known that TCE and CAR-T are usually compared and contrasted with each other, specifically when it comes to CD19-targeted therapies (applicable for cancers and autoimmune diseases), where arguments have been made favoring CAR-T or [87] TCE (BiTE, bispecific T cell engager) [88], over the other. The gene discussed is CD19; the disease is cancer.